Dr. Neela Natarajan, MD

Dr. Natarajan practices at Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University.

Dr. Natarajan's NPI, 1427107010, was assigned on January 10, 2007. Dr. Natarajan holds Massachusetts license 215546.

Dr. Natarajan's primary practice is Emory University Hospital Midtown, at 550 Peachtree Street, NE, Atlanta, GA 30308 in Fulton County. The practice phone is (404) 686-2450.

Dr. Natarajan's primary practice is Emory University Hospital Midtown in Atlanta, Georgia, part of Emory University. Dr. Natarajan is also affiliated with Emory University Hospital. The medical group on file is Emory Clinic. Dmand AI also links Dr. Natarajan to 3 more hospitals, 1 clinical lab and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Natarajan practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Natarajan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Natarajan's licenses on file in 2 states: Massachusetts and Georgia.

CMS data shows 470 Medicare services from Dr. Natarajan across 5 procedure codes in 2024, all of them office visits, for 279 Medicare patients. Medicare paid $38,321 for them. Every service was in an office.

CMS counts 279 Medicare patients who saw Dr. Natarajan in 2024. The largest group is 65 to 74, with 127 patients. 73% of them have high cholesterol, and 71% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Natarajan's median patient age at 70, with 75% women.

In 2024, Dr. Natarajan wrote 905 Medicare Part D claims for 220 patients. 74% of them were for generic drugs. CMS names the drug for 666 of them, across 21 drugs with 11 or more claims each, at $1,650,844 in total drug cost. In 2023, CMS named 851 claims across 22 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Natarajan for performance year 2024, reported through an alternative payment model (APM). Dr. Natarajan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Natarajan as offering telehealth.

CMS Open Payments shows 15 general payments to Dr. Natarajan from 7 drug and device companies from 2016 to 2021. Consulting fees make up the largest share, 81% of the total. Puma Biotechnology, Inc. paid the most, $4,076.